Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Repros Therapeutics ($RPRX) reported that it has been granted a new patent by the USPTO. The patent No. 9,616,074 covers the use of selective progesterone receptor modulators (SPRMs) like telapristone acetate (Proellex) or ulipristal acetate with an off-drug interval (ODI) for the treatment of estrogen-dependent hyperproliferative uterine conditions such as uterine fibroids and endometriosis.
The patent also defines an ODI is the daily administration of the SPRM for a certain period, followed by an ODI sufficient for the patient to menstruate, followed by another period of SPRM treatment. Proellex is currently in Phase 2 development. Repros stock jumped over 10 percent in its previous trading session, trimming its Year to Date loss down to 9 percent.

Aurinia Pharmaceuticals ($AUPH) stock jumped as the company announced inking a new deal with Merck Animal Health. The deal involves transferring global rights to Merck for developing and commercializing voclosporin ophthalmic solution (VOS) for the treatment of dogs with dry eye syndrome. Aurinia is eligible to receive an upfront payment, milestones and royalties on net sales. The company will also retain all rights for human uses.
The deal makes Merck Animal responsible for all remaining clinical development related to VOS in animal health. Aurinia retains all rights for human uses.  The company stock has gained over 218 percent this year so far.


Cardiovascular Systems ($CSII) announced that it has decided to voluntarily recall its 7-10014 Saline Infusion Pump. The company will recall and replace nearly 900 units. The company said that the pumps may be switched to standby mode during use due to electromagnetic interference present in the hospital environment. This malfunctioning may lead to delay in certain coronary artery procedures.

Rigel Pharmaceuticals ($RIGL) reported filing a New Drug Application (NDA) to the FDA seeking approval of fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenia (ITP). The drug candidate has an Orphan Drug indication.

Roche ($RHHBY) announced that Lucentis has been approved by the FDA for the treatment of all forms of diabetic retinopathy. Previously, the VEGF inhibitor was approved to treat diabetic retinopathy with diabetic macular edema. The company said Lucentis is the first and only FDA-approved medication for diabetic retinopathy with or without DME.

Puma Biotechnology ($PBYI) announced that the FDA’s Oncologic Drugs Advisory Committee will be meeting on May 24 to review and discuss its New Drug Application (NDA) seeking approval of neratinib for the treatment of HER2-positive breast cancer.


HTG Molecular Diagnostics ($HTGM) announced inking a new master services agreement with Daiichi Sankyo Company relating to HTG’s VERI/O laboratory. The deal involves the development of a custom assay for the detection of nearly 3,000 mRNA targets using the HTG EdgeSeq technology.

Cardinal Health ($CAH) has signed a new deal with Medtronic for acquiring  its Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion. The deal will be immediately accretive by more than $0.21 to fiscal 2018 non-GAAP EPS, including $100M of inventory step-up costs during the first several quarters, and $0.55 to non-GAAP EPS in fiscal 2019. The transaction will be financed with cash on hand and $4.5 billion in new senior unsecured debt.

Brokerage Ranking
Price Target
Impact on Share Price
BMO Capital Markets
Login to View
AbbVie (ABBV)
FBR & Co
Login to View
Raises Target
Corium International (CORI)
$12.00 -> $13.00
Login to View
Raises Target
UnitedHealth Group (UNH)
$178.00 -> $200.00

Gainers (% price change) Last Trade Change Mkt Cap
Infinity Pharmaceuticals INFI 2.19 +0.35 (19.02%) 104.74M
Alere Inc ALR 49.05 +6.74 (15.93%) 4.26B
Invacare Corporation IVC 11.70 +1.15 (10.90%) 376.25M
Rockwell Medical Inc RMTI 6.61 +0.54 (8.90%) 332.92M
Enzo Biochem, Inc. ENZ 8.65 +0.70 (8.81%) 397.92M
Losers (% price change)
Incyte Corporation INCY 126.07 -14.77 (-10.49%) 26.17B
Tenet Healthcare Corp THC 16.08 -1.40 (-8.01%) 1.60B
Community Health Systems CYH 8.57 -0.53 (-5.82%) 1.01B
Insys Therapeutics Inc INSY 10.57 -0.45 (-4.08%) 745.04M
Eli Lilly and Co LLY 82.38 -3.50 (-4.08%) 90.50B
Most Actives (dollar volume)
Alere Inc ALR 49.05 +6.74 (15.93%) 4.26B
Eli Lilly and Co LLY 82.38 -3.50 (-4.08%) 90.50B
Incyte Corporation INCY 126.07 -14.77 (-10.49%) 26.17B
UnitedHealth Group Inc UNH 167.18 +2.22 (1.35%) 160.64B
Johnson & Johnson JNJ 125.72 +0.73 (0.58%) 339.70B